Orthostatic Intolerance Treatment Durability Study

1 Background and Rationale

Orthostatic intolerance (OI) treatment in pediatric ME/CFS produces substantial symptom improvement in many patients. However, the durability of these improvements after medication withdrawal is unknown. Two possibilities exist:

  • Functional recalibration: OI treatment during the developmental window may enable permanent autonomic system recalibration, allowing medication withdrawal with sustained improvement
  • Symptomatic suppression only: Treatment merely suppresses symptoms while active; withdrawal leads to prompt relapse Distinguishing these possibilities has major clinical implications. If recalibration occurs, children could potentially discontinue medications after a period of stability. If not, long-term treatment may be necessary.

2 Hypothesis

3 Study Design

3.1 Design Overview

Single-arm prospective study with structured medication withdrawal and outcome assessment.

3.2 Participants

  • n=50 pediatric ME/CFS patients (ages 10–17)
  • Currently on stable OI medication regimen (fludrocortisone, midodrine, or combination) for \(\geq\) 6 months
  • Clinical response documented (improvement in orthostatic symptoms, functional capacity)
  • No change in OI medications for past 3 months
  • Willing to attempt medication withdrawal

3.3 Exclusion Criteria

  • Severe ME/CFS (cannot tolerate potential symptom worsening)
  • Parental or patient unwillingness to risk symptom relapse
  • Medical indication for continued OI treatment independent of ME/CFS

3.4 Withdrawal Protocol

  • Baseline assessment: Full OI evaluation (NASA Lean Test, HRV, symptom scales), functional capacity
  • Weeks 1–4: 50% dose reduction of all OI medications
  • Weeks 5–8: Discontinue remaining medications
  • Week 12 (3 months post-withdrawal): Primary endpoint assessment
  • Escape protocol: If intolerable symptoms at any point, return to prior effective dose; patient classified as β€œrelapse”

4 Outcomes

4.1 Primary Outcome

Proportion of patients maintaining \(\geq\) 70% of baseline improvement (measured by composite OI symptom score and functional capacity) at 3 months post-withdrawal without resuming medications.

4.2 Secondary Outcomes

  • Time to symptom relapse (if occurs)
  • Objective OI measures at 3 months (NASA Lean Test heart rate response, HRV)
  • Patient-reported quality of life
  • Proportion requiring medication resumption

5 Analysis Plan

  • Primary analysis: Proportion meeting primary endpoint with 95% confidence interval
  • Kaplan-Meier survival analysis for time to relapse
  • Exploratory: Baseline predictors of sustained improvement (age, disease duration, initial OI severity, HRV parameters)

6 Expected Outcomes and Implications

If \(\geq\) 50% of patients maintain improvement after withdrawal:

  • Supports recalibration hypothesis

  • Suggests time-limited treatment protocols may be appropriate in pediatrics

  • Informs research on inducing similar recalibration in adults If \(<\) 30% maintain improvement:

  • Suggests ongoing treatment is necessary for sustained benefit

  • Informs long-term treatment planning and medication adherence counseling